-
-
The U.S. Food and Drug Administration (FDA) will hold a public meeting of its Endocrinologic and Metabolic Drugs Advisory Committee to discuss the safety and efficacy of new drug application (NDA) 22505, tesamorelin acetate (EGRIFTA®) sterile lyophilized powder for injection, by Theratechnologies, Inc.
-
Due to their impaired immune function, HIV-positive women have a much higher risk of developing cervical and uterine cancers than do women without the disease.
-
New guidelines for the Society for Healthcare Epidemiology of America (SHEA) for health care workers infected with bloodborne viruses include the following procedures at greatest risk of transmission to patients.
-
Do some health care workers infected with HIV or hepatitis B or C pose a risk to their patients? Should they be restricted from performing exposure-prone procedures?
-
Providing case management and care coordination for children is not merely an option for providers in Hawaii's Medicaid program; it is a requirement in their contracts. The agency recently began monitoring how many children are actually receiving these services.
-
State Medicaid programs are taking various approaches to promote care coordination for young children, but few utilize existing maternal child health hotlines or web-based referral strategies.
-
Instead of denying payment outright for preventable conditions as other states do, Maryland is taking a unique approach by instead adjusting payments. The goal is to reduce the statewide averages of these conditions, with the bar raised from year to year, and significant cost savings are expected.
-
-
In this issue: Examining the three arms of the ACCORD trial; and FDA Actions: clopidogrel, dexlansoprazole, and tamsulosin.